CIPLA

📈 Stock & Market Reaction

📊 Financial Performance Cipla reported around 10% year-on-year growth in net profit for the first quarter of FY26, touching about ₹1,298 crore. Revenue rose nearly 4% to around ₹6,950 crore, driven by steady performance in the India and Africa markets. The EBITDA margin remained healthy at around 25.6%, supported by cost control and a better product mix. The domestic “One-India” business crossed ₹3,000 crore in revenue for the quarter, growing around 6% YoY. The US business continued to perform steadily, though pricing pressure in some segments persisted. 📈 Stock & Market Reaction After the Q1 results, Cipla’s stock gained about 3–4% in a single session as investors responded positively to the earnings beat. Over the last one year, the stock has delivered strong returns, though its five-year performance has been more modest compared to peers like Sun Pharma and Dr. Reddy’s. Brokerages have mixed views — some maintain a bullish stance with targets near ₹1,750–₹1,800, while others have turned cautious, lowering targets to around ₹1,500 due to concerns over slower revenue growth and uncertainty in US launches.